BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Solve ME/CFS Initiative - ECPv6.15.17//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Solve ME/CFS Initiative
X-ORIGINAL-URL:https://solvecfs.org
X-WR-CALDESC:Events for Solve ME/CFS Initiative
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260416T083000
DTEND;TZID=America/Los_Angeles:20260416T093000
DTSTAMP:20260720T152256
CREATED:20260225T175057Z
LAST-MODIFIED:20260401T190628Z
UID:43385-1776328200-1776331800@solvecfs.org
SUMMARY:GLP-1 Drugs to Reduce Symptoms in People with ME/CFS and Identify Disease Subgroups
DESCRIPTION:Glucagon-Like Peptide-1 (GLP-1) agonist medications\, like semaglutide\, are injectable or oral drugs that mimic the natural GLP-1 hormone\, which helps regulate insulin levels. Thus\, these medicines help control blood sugar in people with Type 2 diabetes and promote substantial weight loss for individuals with a high body mass index (BMI) by slowing digestion\, reducing appetite\, and increasing insulin release. \n\nBut can they also ease symptoms in people with ME/CFS and identify disease subtypes?\n\nSolve Ramsay Research Grant Program alum Dr. Carmen Scheibenbogen (acting director of the Institute for Medical Immunology of the Charité University Hospital in Berlin) recently received a Solve ME/CFS Catalyst Award for her study evaluating whether semaglutide reduces symptoms and improves quality of life for people with ME/CFS who have high BMI.\n\nIn this free educational webinar hosted by Solve Chief Scientific Officer Dr. Sadie Whittaker and VP of Scientific Programs Dr. Jessica Maya\, Dr. Scheibenbogen will discuss details of her study\, explain how her research will identify biomarkers\, and discuss how these results could help determine which patients are most likely to benefit from treatment.
URL:https://solvecfs.org/event/glp-1-drugs-to-reduce-symptoms-in-people-with-me-cfs-and-identify-disease-subgroups/
CATEGORIES:Research,Webinar
ATTACH;FMTTYPE=image/png:https://solvecfs.org/wp-content/uploads/2026/02/ScheibenbogenMayaWhittakerTw.png
END:VEVENT
END:VCALENDAR